加齢黄斑変性症遺伝子治療の世界市場：市場規模・現状・予測

• 英文タイトル：Global Gene Therapy for Age-related Macular Degeneration Market Size, Status and Forecast 2019-2025

• レポートコード：QYR9ST03893 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療・製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

※当調査レポートでは、加齢黄斑変性症遺伝子治療の世界市場について調査・分析し、加齢黄斑変性症遺伝子治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（網膜下、硝子体内、不特定）、用途別（単独療法、併用療法）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の加齢黄斑変性症遺伝子治療市場動向 ・主要企業別マーケットシェア ・加齢黄斑変性症遺伝子治療の種類別市場規模2014-2019 （網膜下、硝子体内、不特定） ・加齢黄斑変性症遺伝子治療の用途別市場規模2014-2019 （単独療法、併用療法） ・加齢黄斑変性症遺伝子治療の北米市場：主要企業・種類別/用途別市場規模 ・加齢黄斑変性症遺伝子治療のヨーロッパ市場：主要企業・種類別/用途別市場規模 ・加齢黄斑変性症遺伝子治療の中国市場：主要企業・種類別/用途別市場規模 ・加齢黄斑変性症遺伝子治療の日本国内市場：主要企業・種類別/用途別市場規模 ・加齢黄斑変性症遺伝子治療の東南アジア市場：主要企業・種類別/用途別市場規模 ・加齢黄斑変性症遺伝子治療のインド市場：主要企業・種類別/用途別市場規模 ・加齢黄斑変性症遺伝子治療の中南米市場：主要企業・種類別/用途別市場規模 ・主要企業のプロフィール （RetroSense Therapeutics、REGENXBIO、AGTC） ・加齢黄斑変性症遺伝子治療の市場規模予測2019-2025 （種類別、用途別、地域別市場予測） ・アナリストの観点・結論 ...

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market’s growth.
The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).
According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
In 2018, the global Gene Therapy for Age-related Macular Degeneration market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.

The key players covered in this study
RetroSense Therapeutics
REGENXBIO
AGTC
…

Market segment by Type, the product can be split into
Subretinal
Intravitreal
Unspecified

Market segment by Application, split into
Monotherapy
Combination Therapy

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players.
To present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Gene Therapy for Age-related Macular Degeneration are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

レポート目次

---

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (2014-2025)
1.4.2 Subretinal
1.4.3 Intravitreal
1.4.4 Unspecified
1.5 Market by Application
1.5.1 Global Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2025)
1.5.2 Monotherapy
1.5.3 Combination Therapy
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Gene Therapy for Age-related Macular Degeneration Market Size
2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Regions
2.2.1 Gene Therapy for Age-related Macular Degeneration Market Size by Regions (2014-2025)
2.2.2 Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Gene Therapy for Age-related Macular Degeneration Market Size by Manufacturers
3.1.1 Global Gene Therapy for Age-related Macular Degeneration Revenue by Manufacturers (2014-2019)
3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.2 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served
3.3 Key Players Gene Therapy for Age-related Macular Degeneration Product/Solution/Service
3.4 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-2019)
4.2 Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019)

5 United States
5.1 United States Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
5.2 Gene Therapy for Age-related Macular Degeneration Key Players in United States
5.3 United States Gene Therapy for Age-related Macular Degeneration Market Size by Type
5.4 United States Gene Therapy for Age-related Macular Degeneration Market Size by Application

6 Europe
6.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
6.2 Gene Therapy for Age-related Macular Degeneration Key Players in Europe
6.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type
6.4 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application

7 China
7.1 China Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
7.2 Gene Therapy for Age-related Macular Degeneration Key Players in China
7.3 China Gene Therapy for Age-related Macular Degeneration Market Size by Type
7.4 China Gene Therapy for Age-related Macular Degeneration Market Size by Application

8 Japan
8.1 Japan Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
8.2 Gene Therapy for Age-related Macular Degeneration Key Players in Japan
8.3 Japan Gene Therapy for Age-related Macular Degeneration Market Size by Type
8.4 Japan Gene Therapy for Age-related Macular Degeneration Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
9.2 Gene Therapy for Age-related Macular Degeneration Key Players in Southeast Asia
9.3 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Type
9.4 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Application

10 India
10.1 India Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
10.2 Gene Therapy for Age-related Macular Degeneration Key Players in India
10.3 India Gene Therapy for Age-related Macular Degeneration Market Size by Type
10.4 India Gene Therapy for Age-related Macular Degeneration Market Size by Application

11 Central & South America
11.1 Central & South America Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
11.2 Gene Therapy for Age-related Macular Degeneration Key Players in Central & South America
11.3 Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Type
11.4 Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Application

12 International Players Profiles
12.1 RetroSense Therapeutics
12.1.1 RetroSense Therapeutics Company Details
12.1.2 Company Description and Business Overview
12.1.3 Gene Therapy for Age-related Macular Degeneration Introduction
12.1.4 RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)
12.1.5 RetroSense Therapeutics Recent Development
12.2 REGENXBIO
12.2.1 REGENXBIO Company Details
12.2.2 Company Description and Business Overview
12.2.3 Gene Therapy for Age-related Macular Degeneration Introduction
12.2.4 REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)
12.2.5 REGENXBIO Recent Development
12.3 AGTC
12.3.1 AGTC Company Details
12.3.2 Company Description and Business Overview
12.3.3 Gene Therapy for Age-related Macular Degeneration Introduction
12.3.4 AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)
12.3.5 AGTC Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

List of Tables and Figures

Table Gene Therapy for Age-related Macular Degeneration Key Market Segments
Table Key Players Gene Therapy for Age-related Macular Degeneration Covered
Table Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type 2014-2025 (Million US$)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size Market Share by Type 2014-2025
Figure Subretinal Figures
Table Key Players of Subretinal
Figure Intravitreal Figures
Table Key Players of Intravitreal
Figure Unspecified Figures
Table Key Players of Unspecified
Table Global Gene Therapy for Age-related Macular Degeneration Market Size Growth by Application 2014-2025 (Million US$)
Figure Monotherapy Case Studies
Figure Combination Therapy Case Studies
Figure Gene Therapy for Age-related Macular Degeneration Report Years Considered
Table Global Gene Therapy for Age-related Macular Degeneration Market Size 2014-2025 (Million US$)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Gene Therapy for Age-related Macular Degeneration Market Size by Regions 2014-2025 (Million US$)
Table Global Gene Therapy for Age-related Macular Degeneration Market Size by Regions 2014-2019 (Million US$)
Table Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions 2014-2019
Figure Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions 2014-2019
Figure Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions 2019
Table Market Top Trends
Table Global Gene Therapy for Age-related Macular Degeneration Revenue by Manufacturers (2014-2019) (Million US$)
Table Global Gene Therapy for Age-related Macular Degeneration Market Share by Manufacturers (2014-2019)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Share by Manufacturers in 2018
Table Global Gene Therapy for Age-related Macular Degeneration Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Gene Therapy for Age-related Macular Degeneration Product/Solution/Service
Table Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-2019) (Million US$)
Table Global Gene Therapy for Age-related Macular Degeneration Market Size Share by Type (2014-2019)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size Market Share by Type (2014-2019)
Table Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019) (Million US$)
Table Global Gene Therapy for Age-related Macular Degeneration Market Size Share by Application (2014-2019)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size Market Share by Application (2014-2019)
Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application in 2018
Figure United States Gene Therapy for Age-related Macular Degeneration Market Size 2014-2019 (Million US$)
Table United States Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2018-2019) (Million US$)
Table United States Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2018-2019)
Table United States Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-2019) (Million US$)
Table United States Gene Therapy for Age-related Macular Degeneration Market Share by Type (2014-2019)
Table United States Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019) (Million US$)
Table United States Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2019)
Figure Europe Gene Therapy for Age-related Macular Degeneration Market Size 2014-2019 (Million US$)
Table Europe Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2018-2019) (Million US$)
Table Europe Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2018-2019)
Table Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-2019) (Million US$)
Table Europe Gene Therapy for Age-related Macular Degeneration Market Share by Type (2014-2019)
Table Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019) (Million US$)
Table Europe Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2019)
Figure China Gene Therapy for Age-related Macular Degeneration Market Size 2014-2019 (Million US$)
Table China Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2018-2019) (Million US$)
Table China Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2018-2019)
Table China Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-20189) (Million US$)
Table China Gene Therapy for Age-related Macular Degeneration Market Share by Type (2014-2019)
Table China Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019) (Million US$)
Table China Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2019)
Figure Japan Gene Therapy for Age-related Macular Degeneration Market Size 2014-2019 (Million US$)
Table Japan Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2018-2019) (Million US$)
Table Japan Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2018-2019)
Table Japan Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-2019) (Million US$)
Table Japan Gene Therapy for Age-related Macular Degeneration Market Share by Type (2014-2019)
Table Japan Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019) (Million US$)
Table Japan Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2019)
Figure Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2018-2019)
Table Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-2019) (Million US$)
Table Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Share by Type (2014-2019)
Table Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019) (Million US$)
Table Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2019)
Figure India Gene Therapy for Age-related Macular Degeneration Market Size 2014-2019 (Million US$)
Table India Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2018-2019) (Million US$)
Table India Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2018-2019)
Table India Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-2019) (Million US$)
Table India Gene Therapy for Age-related Macular Degeneration Market Share by Type (2014-2019)
Table India Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019) (Million US$)
Table India Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2019)
Figure Central & South America Gene Therapy for Age-related Macular Degeneration Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2018-2019)
Table Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-2019) (Million US$)
Table Central & South America Gene Therapy for Age-related Macular Degeneration Market Share by Type (2014-2019)
Table Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019) (Million US$)
Table Central & South America Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2019)
Table RetroSense Therapeutics Company Details
Table RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2014-2019) (Million US$)
Figure RetroSense Therapeutics Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)
Table RetroSense Therapeutics Recent Development
Table REGENXBIO Company Details
Table REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)(Million US$)
Figure REGENXBIO Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)
Table REGENXBIO Recent Development
Table AGTC Company Details
Table AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)(Million US$)
Figure AGTC Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)
Table AGTC Recent Development
Table Global Gene Therapy for Age-related Macular Degeneration Market Size by Regions (Million US$) 2019-2025
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size Share by Regions (2019-2025)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size Share by Regions in 2025
Figure United States Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2019-2025)(Million USD)
Figure Europe Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2019-2025)(Million USD)
Figure China Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2019-2025)(Million USD)
Figure Japan Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2019-2025)(Million USD)
Figure India Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2019-2025)(Million USD)
Table Global Gene Therapy for Age-related Macular Degeneration Market Size by Product (2019-2025) (Million US$)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size by Product (2019-2025)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size by Product in 2025
Table Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2019-2025) (Million US$)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2019-2025)
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

---